arrow
S

Sung-Yun Pai

national institutes of healthChief of the Immune Deficiency Cellular Therapy Program
H指数:55
被引数:1.2万

个人简介

Dr. Sung-Yun Pai received her M.D. degree from Harvard Medical School where she worked in the laboratory of Dr. Barbara Bierer on the cellular biology of calcineurin and mechanism of action of cyclosporine, tacrolimus, and sirolimus. She trained in pediatrics at Boston Children’s Hospital and pediatric hematology-oncology at Boston Children’s Hospital and Dana-Farber Cancer Institute. There she performed post-doctoral work in the laboratories of Drs. Jeffrey Leiden, I-Cheng Ho, and Laurie Glimcher demonstrating the critical roles of the transcription factor GATA3 in thymocyte development, T helper 2 cell specification and function, as well as in CD8 T cells, invariant NK-T cells, and collaboratively in breast cancer and keratinocyte development. As faculty she specialized in clinical hematopoietic stem cell transplantation for children with inborn errors of immunity and led a research program focused on development, implementation, and analysis of clinical trials of transplantation and gene therapy for these disorders. She was appointed to Associate Professor at Harvard Medical School in 2016 and served as Associate Director then Co-Director of the Gene Therapy Program at Boston Children’s Hospital. In 2020, she moved to the National Cancer Institute and National Institute of Allergy and Infectious Diseases to assume the role of Chief of the Immune Deficiency Cellular Therapy Program. Key areas of focus include severe combined immunodeficiency, Wiskott-Aldrich syndrome, and DOCK8 deficiency.

教育背景

暂无内容

工作经历

  • 2020.01 – 至今

    National Cancer Institute

    Chief of the Immune Deficiency Cellular Therapy Program

荣誉奖项

暂无内容

IMPACT (Immune Monitoring and Phenotype Assessment of Clinical Trajectory) for Patients With Inborn Errors of Immunity From the Primary Immune Deficiency Treatment Consortium (PIDTC)

免疫监测和表型评估对临床轨迹的影响(IMPACT),用于原发性免疫缺陷治疗联盟(PIDTC)中免疫先天性错误疾病患者

2026-08-010
OAAI
Resolution of PML after Treatment with Virus-Specific T Cells and HCT

病毒特异性T细胞和HCT治疗后PML的缓解

2026-05-280
PRE
Cryptosporidiosis in Inborn Errors of Immunity: A Single Center Cohort and Review of the Literature

免疫缺陷病中的隐孢子虫病:一项单中心队列研究及文献综述

2026-01-010
PRE
Clinical spectrum of Wiskott-Aldrich syndrome carriers: Self-reported survey of 193 carriers

Wiskott-Aldrich综合征携带者的临床谱:193名携带者的自我报告调查

2025-12-170
PRE
Umbilical Cord Blood Transplantation Provides an Alternative for Patients with Chronic Granulomatous Disease Lacking HLA-Matched Donors: a PIDTC Report

脐带血移植为缺乏HLA匹配供体的慢性肉芽肿病患者提供了替代方案:一份PIDTC报告

2025-10-020
PRE
Usefulness and Limitations of Polymerase Chain Reaction (PCR) for the Diagnosis and Management of Toxoplasmosis Following Allogeneic Hematopoietic Cell Transplant: Single-center Experience With 31 Patients Over 16 Years

聚合酶链式反应(PCR)在异基因造血细胞移植后弓形虫病诊断与管理中的有效性与局限性:单中心16年经验,涉及31例患者

2025-08-050
OAAI
Restoration of the human skin microbiome following immune recovery after hematopoietic stem cell transplantation

造血干细胞移植后免疫恢复期间人体皮肤微生物组的恢复

2025-07-280
OAAI
Allogeneic hematopoietic stem cell transplantation for STAT3 hyper-IgE syndrome: a worldwide study

异基因造血干细胞移植治疗STAT3高IgE综合征:一项全球性研究

2025-06-230
OAAI
Association of busulfan exposure and outcomes after HCT for patients with an inborn error of immunity
2024-09-271
OAAI
Allogeneic hematopoietic cell transplantation is effective for p47phox chronic granulomatous disease: A Primary Immune Deficiency Treatment Consortium study
2024-05-013
PRE
Antiviral cellular therapy for enhancing T-cell reconstitution before or after hematopoietic stem cell transplantation (ACES): a two-arm, open label phase II interventional trial of pediatric patients with risk factor assessment
2024-04-183
OAAI
Secondary bone marrow graft loss after third-party virus-specific T cell infusion: Case report of a rare complication
2024-03-292
OAAI
Posttransplantation late complications increase over time for patients with SCID: A Primary Immune Deficiency Treatment Consortium (PIDTC) landmark study
2024-01-014
OAAI
Intestinal microbiome and metabolome signatures in patients with chronic granulomatous disease
2023-12-018
OAAI
Alemtuzumab and CXCL9 levels predict likelihood of sustained engraftment after reduced-intensity conditioning HCT
2023-07-181
OAAI
Measuring the effect of newborn screening on survival after haematopoietic cell transplantation for severe combined immunodeficiency: a 36-year longitudinal study from the Primary Immune DeficiencyTreatment Consortium
LANCET
IF88.5
2023-07-0130
OAAI
The diagnosis of severe combined immunodeficiency (SCID): The Primary Immune Deficiency Treatment Consortium (PIDTC) 2022 Definitions
2023-02-0136
OAAI
The diagnosis of severe combined immunodeficiency: Implementation of the PIDTC 2022 Definitions
2023-02-0119
OAAI